Published research has described gastrointestinal adverse events as dose-related
Additionally, exenatide increased cerebral glucose metabolism in regions associated with glucose homeostasis, appetite, and food reward, as observed through [(18)F]2-fluoro-2-deoxy-d-glucose PET/CT scans [17,18,19]
And, avoid eating too close to bedtime
EMERGING RISK SIGNALS A recent analysis published in The British Medical Journal (BMJ) Medicine has found that patients who discontinue GLP-1 therapies may face increased cardiovascular risks
These medications include semaglutide (Ozempic, Wegovy, Rybelsus), liraglutide (Victoza, Saxenda), and dulaglutide (Trulicity)
It requires careful management to prevent complications and maintain a good quality of life